NC-PERCONA
23.5.2023 15:01:36 CEST | Business Wire | Press release
Percona, a leader in enterprise-grade open source database software, support, and services, today announced the initial findings of its State of Open Source Database Survey report for 2023 during its annual Percona Live conference. According to the survey of nearly 300 database professionals working in companies ranging in size from small-to-medium-sized business to large enterprise, the database market is currently in a period of stasis around database deployments and changes, most likely due to economic uncertainty and post-COVID-19 recovery. The research indicates that most organizations are not planning to make significant alterations to their database strategies over the course of the next three years.
Alongside this broader revelation, the study sheds light on a number of database operations concerns for organizations, including challenges around developer agility, and significant factors driving the choice between deploying open source or proprietary databases.
Findings in the 2023 State of Open Source Database Survey include:
-
More respondents indicate their organizations are doing well with a host of database operations metrics than they are with meeting developer needs:
- More than 70 percent of respondents say they are doing somewhat or extremely well with database reliability, performance, security, privacy, scalability and backup reliability and integrity.
- Conversely, meeting the needs of developers placed last on the list of 14 operational metrics collected, with only 55 percent of respondents saying they are doing well in developer agility.
-
Comparing large enterprises and small-to-medium businesses, the research shows that bigger companies tend to have more tools and automation deployed to help their teams:
- Large enterprises are much more likely to use database monitoring and management solutions, with 93 percent of organizations having such tools in place. Conversely, only 57 percent of small businesses have database monitoring and management solutions deployed.
- Small companies are much more likely to use on-premises and cloud services to host their databases (49 percent) compared to 26 percent of large enterprises. Large enterprises are also much more likely to use DBaaS offerings (32 percent of deployments).
“Our report indicates that database deployment strategies are expected to remain static for the next few years, with levels of usage remaining consistent across all categories of relational and non-relational databases,” said Joe Brockmeier, Head of Community at Percona. “We’re seeing caution around making significant changes to deployments following the large-scale digital transformation undertaken during the pandemic and the uncertain economic climate the world is facing in 2023. Teams want to improve how they manage, monitor and run those deployments rather than implementing more changes.”
Further findings include:
- When asked about what drove their choice to use open source databases, respondents most often cited cost reductions (83 percent rated as somewhat or extremely significant) and developer choice (81 percent), followed by faster deployment (75 percent) and then security and more control (73 percent each).
- For respondents that implemented proprietary databases, the findings are very different – the biggest factors are greater stability (68 percent), more security (63 percent) and regulatory compliance (61).
- Developer choice was not in the top ten reasons to deploy proprietary databases, pointing to a much larger preference for open source solutions for the developer community.
-
The majority of respondents say their organizations rely on both relational and non-relational databases – 99 percent of respondents run at least one relational database, and 86 percent run at least one non-relational database.
- MySQL is the most popular relational database, followed by PostgreSQL and Oracle Server at 57, 48 and 47 percent respectively.
- MongoDB is the most commonly deployed non-relational database, followed by Couchbase and Redis.
“Developers prefer open source software where they have choice and autonomy over how they can architect and build their applications. The flexibility and performance benefits aside, open source also helps companies save on costs compared to running proprietary databases, which can’t be ignored in today’s economy. However, companies can still improve how they run and manage those installations, and that is where Percona can really help,” said Ann Schlemmer, CEO at Percona.
Speakers at this year’s Percona Live will discuss these and other findings from the 2023 survey. Percona Live is sponsored by a range of companies in the data and database markets, including Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver.
If you would like to be notified when the full report from this survey is made available, please send an email with the request to: databasesurvey@percona.com
About Percona
Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries, creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.
Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.
Databases run better with Percona.
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005396/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
